tiprankstipranks
Trending News
More News >
JD Health International, Inc. (HK:6618)
:6618
Hong Kong Market
Advertisement

JD Health International, Inc. (6618) Earnings Dates, Call Summary & Reports

Compare
13 Followers

Earnings Data

Report Date
Aug 26, 2025
TBA (Confirmed)
Period Ending
2025 (Q2)
Consensus EPS Forecast
1.09
Last Year’s EPS
0.65
Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings

Earnings Call Summary

Q4 2024
Earnings Call Date:Mar 06, 2025|
% Change Since: 14.83%|
Earnings Call Sentiment|Positive
JD Health demonstrated strong performance in 2024 with significant revenue growth and expansion in AI and B2C leadership. Despite some increases in expenses and slower direct sales growth, the company's strategic initiatives and robust service revenue highlight a positive outlook.
Company Guidance -
Q2 2025
During the JD Health International 2024 Annual Results Conference Call, the company reported a full-year revenue of RMB58.16 billion, marking an 8.6% year-over-year increase. Excluding the pandemic-related high comparison base from the first quarter, revenue growth in the second to fourth quarters was 13.4% year-over-year. The annual active user count exceeded 183 million, with over 498,000 average daily online consultations. JD Health's direct sales revenue was RMB48.8 billion, a 6.9% increase from the previous year, driven by strong performance in pharmaceuticals. Service revenue for 2024 reached RMB9.36 billion, growing 18.9% year-over-year and comprising 16.1% of total revenue. The company's gross profit margin improved by 17 basis points to 22.9%, and non-IFRS net profit rose by 15.9% to RMB4.8 billion, achieving a margin of 8.2%. JD Health continued to enhance its omnichannel and AI initiatives, maintaining a robust cash position with RMB59.42 billion in reserves by year-end.
Robust Revenue Growth
JD Health achieved a full year revenue of RMB58.16 billion in 2024, up 8.6% year-over-year, with significant growth in pharmaceutical sales and non-pharmaceutical segments.
Expansion of B2C Leadership
The company solidified its B2C leadership by increasing its omnichannel initiatives and leadership in pharmaceuticals, with a focus on imported drugs and innovative treatments.
AI Innovations
JD Health launched Jingyi Qianxun, a large language model, and other AI-powered tools to enhance doctor productivity and user experience, aiming for AI-powered transformation in healthcare.
Increased Service Revenue
Service revenue surpassed RMB9.36 billion for the year, marking an 18.9% increase year-over-year, with significant contributions from platform commissions and advertising revenue.
High-Quality Active User Base
The annual active user count exceeded 183 million, with an average daily online consultation volume of over 498,000, demonstrating strong user engagement.

JD Health International, Inc. (HK:6618) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

HK:6618 Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 26, 2025
2025 (Q2)
1.09 / -
0.65
Mar 06, 2025
2024 (Q4)
0.69 / 0.74
0.2271.58% (+0.54)
Aug 15, 2024
2024 (Q2)
0.72 / 0.71
0.53632.65% (+0.17)
Mar 20, 2024
2023 (Q4)
0.22 / 0.20
0.273-26.80% (-0.07)
Aug 16, 2023
2023 (Q2)
0.11 / 0.54
0.077600.00% (+0.46)
Mar 22, 2023
2022 (Q4)
0.34 / 0.27
0.2624.17% (+0.01)
Aug 23, 2022
2022 (Q2)
0.23 / 0.08
-0.164146.67% (+0.24)
Mar 28, 2022
2021 (Q4)
0.19 / 0.26
-4.663105.62% (+4.93)
Aug 24, 2021
2021 (Q2)
0.47 / -0.16
-2.0391.92% (+1.87)
Mar 29, 2021
2020 (Q4)
- / -4.27
-0.422-911.14% (-3.85)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

HK:6618 Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 06, 2025
HK$38.65HK$40.80+5.56%
Aug 15, 2024
HK$20.45HK$19.82-3.08%
Mar 20, 2024
HK$32.15HK$32.05-0.31%
Aug 16, 2023
HK$50.20HK$50.55+0.70%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does JD Health International, Inc. (HK:6618) report earnings?
JD Health International, Inc. (HK:6618) is schdueled to report earning on Aug 26, 2025, TBA (Confirmed).
    What is JD Health International, Inc. (HK:6618) earnings time?
    JD Health International, Inc. (HK:6618) earnings time is at Aug 26, 2025, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of JD Health International, Inc. stock?
          The P/E ratio of JD Health International, Inc. is N/A.
            What is HK:6618 EPS forecast?
            HK:6618 EPS forecast for the fiscal quarter 2025 (Q2) is 1.09.
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis